CHRYSALIS, CHRYSALIS-2 Updates Add Support For Amivantamab Use In Specific NSCLC Populations
From ASCO 2022 Annual Meeting:
Amivantamab shows activity in NSCLC patients with a primary MET exon 14 skipping mutation and when used in combination with lazertinib for those with EGFR mutations who have progressed after osimertinib and chemotherapy